Economic information and modeling reportBudget impact model
Cost assumptions
18 evidence topics · 17 sources
Budget impact model of cretostimogene grenadenorepvec: cost assumptions
No evidence found.
Cretostimogene grenadenorepvec price
No evidence found.
Cretostimogene grenadenorepvec dosing schedule in BOND-003
Nadofaragene firadenovec wholesale acquisition cost
| Field | Value |
|---|---|
| NDC | “55566-1050-01” |
| Dosage form | “box” |
| Pack size | “4 vials x 20 ml” |
| WAC | “$62,740.70” |
Nadofaragene firadenovec dosing
Nogapendekin alfa inbakicept wholesale acquisition cost
| Field | Value |
|---|---|
| Marketed product | “ANKTIVA 400 mcg/0.4 mL” |
| NDC | “81481-803-01” |
| WAC price (400 mcg/0.4 mL vial) | “$35,800.00” |
Nogapendekin alfa inbakicept dosing
Pembrolizumab list price
Pembrolizumab dosing in BCG-unresponsive NMIBC
Gemcitabine intravesical system wholesale acquisition cost
No evidence found.
Gemcitabine intravesical system dosing
Medicare Part B payment limits for comparator agents, fourth quarter of 2026
| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
|---|---|---|---|---|
| J9029 nadofaragene firadenovec (Adstiladrin) | “Instill adstiladrin, tx dose” | “PER THERAPEUTIC DOSE” | “65200.563” | “20.000” |
| J9028 nogapendekin alfa inbakicept (Anktiva) | “Inj, nogapendekin pmln, 1mcg” | “1 MCG” | “94.139” | “20.000” |
| J9183 gemcitabine intravesical system (Inlexzo) | “Gemcitabine intravesical sys” | “225 MG” | “73054.053” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J9030 BCG live intravesical | “Bcg live intravesical 1mg” | “1 MG” | “3.532” | “20.000” |
| J9357 valrubicin | “Valrubicin injection” | “200 MG” | “1230.664” | “20.000” |
| J9201 gemcitabine | “In gemcitabine hcl nos 200mg” | “200 MG” | “2.734” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| J9280 mitomycin | “Mitomycin injection” | “5 MG” | “34.838” | “20.000” |
Medicare physician fee schedule relative value units for office-based instillation, surveillance, and evaluation services, 2026
| CPT code | Description | Non-facility total RVU | Facility total RVU | Conversion factor |
|---|---|---|---|---|
| 51720 | “Treatment of bladder lesion” | “2.75” | “1.14” | “33.4009” |
| 51701 | “Insert bladder catheter” | “1.36” | “0.66” | “33.4009” |
| 52000 | “Cystourethroscopy” | “6.46” | “2.13” | “33.4009” |
| 52204 | “Cystoscopy w/biopsy(s)” | “10.64” | “3.80” | “33.4009” |
| 88112 | “Cytopath cell enhance tech” | “1.96” | “1.96” | “33.4009” |
| 88120 | “Cytp urne 3-5 probes ea spec” | “16.23” | “16.23” | “33.4009” |
| 74178 | “Ct abd&plv wo cntr flwd cntr” | “10.12” | “10.12” | “33.4009” |
| 99214 | “Office o/p est mod 30 min” | “4.06” | “2.53” | “33.4009” |
Medicare physician fee schedule relative value units for transurethral resection and radical cystectomy, 2026
| CPT code | Description | Facility total RVU | Global days | Conversion factor |
|---|---|---|---|---|
| 52234 | “Cystoscopy and treatment” | “6.49” | “000” | “33.4009” |
| 52235 | “Cystoscopy and treatment” | “7.62” | “000” | “33.4009” |
| 52240 | “Cystoscopy and treatment” | “10.31” | “000” | “33.4009” |
| 51570 | “Removal of bladder” | “39.05” | “090” | “33.4009” |
| 51575 | “Removal of bladder & nodes” | “48.18” | “090” | “33.4009” |
| 51590 | “Remove bladder/revise tract” | “51.25” | “090” | “33.4009” |
| 51595 | “Remove bladder/revise tract” | “57.93” | “090” | “33.4009” |
| 51596 | “Remove bladder/create pouch” | “62.52” | “090” | “33.4009” |
Unit cost inputs in a published budget impact model
Three-month Medicare costs in a published cost-effectiveness model, 2024
“We calculated 2024 U.S. healthcare costs from a Medicare payer perspective. Costs were obtained for drugs, procedures, tests, and hospital admissions through Medicare payment schedules for CPT, DRG, and HCPCS codes (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cost sources in a published cost-per-responder model
Placeholder drug prices in the ICER review
“Since the prices for nadofaragene firadenovec and oportuzumab monatox were not available at the time of the report, the price for nadofaragene firadenovec was set to equal the annual price of pembrolizumab ($164,337), whereas oportuzumab was set at $150,000 per year net of all rebates based on analyst estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of care after BCG with and without progression
“Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annualized HRU and mean medical costs (2020 United States dollars) were estimated and compared between patients with versus without progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote